Title |
Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration
|
---|---|
Published in |
Drug Design, Development and Therapy, June 2013
|
DOI | 10.2147/dddt.s43470 |
Pubmed ID | |
Authors |
Paris Tranos, Athanasios Vacalis, Solon Asteriadis, Stavrenia Koukoula, Athanasios Vachtsevanos, Georgia Perganta, Ilias Georgalas |
Abstract |
Age-related macular degeneration (AMD) is the main cause of visual impairment and blindness in people aged over 65 years in developed countries. Vascular endothelial growth factor (VEGF) is a positive regulator of angiogenesis and its proven role in the pathological neovascularization in wet AMD has provided evidence for the use of anti-VEGF agents as potential therapies. In this study, we review the literature for the possible causes of failure after treatment with anti-VEGF agents and attempt to propose an algorithm of suggestive actions to increase the chances of successful management of such difficult cases. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
France | 1 | 2% |
Switzerland | 1 | 2% |
Unknown | 60 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 10 | 16% |
Student > Master | 10 | 16% |
Researcher | 8 | 13% |
Student > Bachelor | 5 | 8% |
Professor | 5 | 8% |
Other | 10 | 16% |
Unknown | 14 | 23% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 19 | 31% |
Agricultural and Biological Sciences | 10 | 16% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 6% |
Biochemistry, Genetics and Molecular Biology | 4 | 6% |
Economics, Econometrics and Finance | 2 | 3% |
Other | 7 | 11% |
Unknown | 16 | 26% |